trial · primary record
Deucravacitinib
Plaque Psoriasis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 3040 |
| Primary completion | 2031-01-16 |
| Primary endpoint | Composite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularization |
| Registry ID | NCT07116967 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:44:30.942Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07116967
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- DEUCRAVACITINIB · approval
- Deucravacitinib · compound